Skip to main
RMD

ResMed (RMD) Stock Forecast & Price Target

ResMed (RMD) Analyst Ratings

Based on 10 analyst ratings
Hold
Strong Buy 0%
Buy 20%
Hold 80%
Sell 0%
Strong Sell 0%

Bulls say

ResMed is well-positioned due to their large market share in the Americas, recent focus on digital health, and strong financial performance with a solid gross margin of 62.3%. Despite a downwards trend in projected revenue growth in the next few years, the company's acquisition of MatrixCare for $490m highlights its commitment to growth through strategic acquisitions. ResMed's efforts to integrate sustainability into its strategy, from product safety to environmental initiatives, also showcase the company's long-term vision and commitment to responsible business practices.

Bears say

ResMed is suffering from potential disruptions in the sleep apnea market as GLP-1 drugs and expanded indications may reduce PAP volumes, despite their projection of continued growth in devices, masks, and SaaS revenue. Additionally, their gross margin of 61% and expansive global market may not be enough to offset this potential disruption, leading to a Hold rating.

ResMed (RMD) has been analyzed by 10 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 20% recommend Buy, 80% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ResMed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ResMed (RMD) Forecast

Analysts have given ResMed (RMD) a Hold based on their latest research and market trends.

According to 10 analysts, ResMed (RMD) has a Hold consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $238.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $238.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ResMed (RMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.